Cargando…

MUC5B promoter variant rs35705950, rare but significant susceptibility locus in rheumatoid arthritis-interstitial lung disease with usual interstitial pneumonia in Asian populations

BACKGROUND: MUC5B variant rs35705950 is the common and most significant risk variant for rheumatoid arthritis-interstitial lung disease (RA-ILD) in Western populations. However, little is known about its significant association with RA-ILD in Asian populations. We here investigate the association of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Joo, Young Bin, Ahn, Soo Min, Bang, So-Young, Park, Youngho, Hong, Su Jin, Lee, Youkyung, Cho, Soo-Kyung, Choi, Chan-Bum, Sung, Yoon-Kyoung, Kim, Tae-Hwan, Jun, Jae-Bum, Yoo, Dae Hyun, Bae, Sang-Cheol, Lee, Hye-Soon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Rheumatoid Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806030/ https://www.ncbi.nlm.nih.gov/pubmed/36581384 http://dx.doi.org/10.1136/rmdopen-2022-002790

Ejemplares similares

Lifetime risk of rheumatoid arthritis-associated interstitial lung disease in MUC5B mutation carriers
por: Palomäki, Antti, et al.
Publicado: (2021)

Association of the RPA3-UMAD1 locus with interstitial lung diseases complicated with rheumatoid arthritis in Japanese
por: Shirai, Yuya, et al.
Publicado: (2020)

Genome-wide association study in a Korean population identifies six novel susceptibility loci for rheumatoid arthritis
por: Kwon, Young-Chang, et al.
Publicado: (2020)

Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic
por: Druce, Katie L, et al.
Publicado: (2017)

A Risk Score to Detect Subclinical Rheumatoid Arthritis–Associated Interstitial Lung Disease
por: Juge, Pierre‐Antoine, et al.
Publicado: (2022)

Association of a FAM13A variant with interstitial lung disease in Japanese rheumatoid arthritis
por: Higuchi, Takashi, et al.
Publicado: (2023)

Patient-level factors predictive of interstitial lung disease in rheumatoid arthritis: a systematic review
por: Matteson, Eric L., et al.
Publicado: (2023)

Increased mortality in patients with RA-associated interstitial lung disease: data from a French administrative healthcare database
por: Juge, Pierre-Antoine, et al.
Publicado: (2023)

Analysis of risk factors of mortality in rheumatoid arthritis patients with interstitial lung disease: a nationwide, population-based cohort study in Taiwan
por: Ng, Kooi-Heng, et al.
Publicado: (2022)

Efficacy of non-conventional synthetic DMARDs for patients with rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis
por: Yuan, Haoming, et al.
Publicado: (2023)

The Association between MUC5B Rs35705950 and Risks of Idiopathic Interstitial Pneumonia, Systemic Sclerosis Interstitial Lung Disease, and Familial Interstitial Pneumonia: A Meta-Analysis
por: LOU, Huai-Qing, et al.
Publicado: (2020)

Large-scale meta-analysis across East Asian and European populations updated genetic architecture and variant-driven biology of rheumatoid arthritis, identifying 11 novel susceptibility loci
por: Ha, Eunji, et al.
Publicado: (2021)

Smartphone‐Assisted Patient‐Initiated Care Versus Usual Care in Patients With Rheumatoid Arthritis and Low Disease Activity: A Randomized Controlled Trial
por: Seppen, Bart, et al.
Publicado: (2022)

Allele-specific protein binding within the CD40 locus in human synovial fibroblasts and immune cells
por: Moser, Larissa, et al.
Publicado: (2023)

Novel Rheumatoid Arthritis Susceptibility Locus at 22q12 Identified in an Extended UK Genome-Wide Association Study
por: Orozco, Gisela, et al.
Publicado: (2014)

Patient Reported Outcome Measures for Rheumatoid Arthritis Disease Activity: a systematic review following COSMIN guidelines
por: Pickles, Tim, et al.
Publicado: (2022)

Contribution of a European‐Prevalent Variant near CD83 and an East Asian–Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome‐Wide Association Study Meta‐Analyses
por: Bing, Nan, et al.
Publicado: (2021)

Antibodies against citrullinated proteins of IgA isotype are associated with progression to rheumatoid arthritis in individuals at-risk
por: Sokolova, Maria V, et al.
Publicado: (2023)

Association between social deprivation and disease activity in rheumatoid arthritis: a systematic literature review
por: Dey, Mrinalini, et al.
Publicado: (2022)

Predictors of Change in Bodily Pain in Early Rheumatoid Arthritis: An Inception Cohort Study
por: McWilliams, Daniel F, et al.
Publicado: (2012)

The Impact of Inflammation on Metabolomic Profiles in Patients With Arthritis
por: Young, Stephen P, et al.
Publicado: (2013)

HLA–DRB1 Amino Acid Positions 11/13, 71, and 74 Are Associated With Inflammation Level, Disease Activity, and the Health Assessment Questionnaire Score in Patients With Inflammatory Polyarthritis
por: Ling, Stephanie F., et al.
Publicado: (2016)

Metabolic Profiling Predicts Response to Anti–Tumor Necrosis Factor α Therapy in Patients With Rheumatoid Arthritis
por: Kapoor, Sabrina R, et al.
Publicado: (2013)

A Multicenter, Prospective, Randomized, Parallel‐Group Trial on the Effects of Temporary Methotrexate Discontinuation for One Week Versus Two Weeks on Seasonal Influenza Vaccination in Patients With Rheumatoid Arthritis
por: Park, Jin Kyun, et al.
Publicado: (2022)

Era of biosimilars in rheumatology: reshaping the healthcare environment
por: Smolen, Josef S, et al.
Publicado: (2019)

Impact of early age at menopause on disease outcomes in postmenopausal women with rheumatoid arthritis: a large observational cohort study of Korean patients with rheumatoid arthritis
por: Park, Eun Hye, et al.
Publicado: (2023)

Recognition of Amino Acid Motifs, Rather Than Specific Proteins, by Human Plasma Cell–Derived Monoclonal Antibodies to Posttranslationally Modified Proteins in Rheumatoid Arthritis
por: Steen, Johanna, et al.
Publicado: (2019)

Identification of Distinct Disease Activity Trajectories in Methotrexate‐Naive Patients With Rheumatoid Arthritis Receiving Tofacitinib Over Twenty‐Four Months
por: Bykerk, Vivian P., et al.
Publicado: (2021)

Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6
por: van Vollenhoven, Ronald F., et al.
Publicado: (2018)

Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
por: Combe, Bernard, et al.
Publicado: (2021)

Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study
por: Buttgereit, Frank, et al.
Publicado: (2019)

Identification of MYH9 as a key regulator for synoviocyte migration and invasion through secretome profiling
por: Lee, Saseong, et al.
Publicado: (2023)

Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial
por: Strand, Vibeke, et al.
Publicado: (2016)

Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study
por: Calabrese, Leonard H., et al.
Publicado: (2020)

Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study
por: Schiff, Michael, et al.
Publicado: (2015)

Evaluation of the Short‐, Mid‐, and Long‐Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis
por: van Vollenhoven, Ronald, et al.
Publicado: (2019)

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
por: Cohen, Stanley B, et al.
Publicado: (2020)

Association Between Genetic Variation in FOXO3 and Reductions in Inflammation and Disease Activity in Inflammatory Polyarthritis
por: Viatte, Sebastien, et al.
Publicado: (2016)

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)
por: Tanaka, Yoshiya, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6kgpd8dagbipsfqo1tjjsan38j